An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses.
about
Glucopyranosyl lipid A adjuvant significantly enhances HIV specific T and B cell responses elicited by a DNA-MVA-protein vaccine regimenA candidate HIV/AIDS vaccine (MVA-B) lacking vaccinia virus gene C6L enhances memory HIV-1-specific T-cell responsesThe failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?The aftermath of the Merck's HIV vaccine trialHIV-1 prophylactic vaccines: state of the artNonhuman primate models for HIV/AIDS vaccine developmentPoxvirus vectors as HIV/AIDS vaccines in humansThe evolution of poxvirus vaccinesA global approach to HIV-1 vaccine developmentImmunogenic profiling in mice of a HIV/AIDS vaccine candidate (MVA-B) expressing four HIV-1 antigens and potentiation by specific gene deletionsEarly Interferon Therapy for Hepatitis C Virus Infection Rescues Polyfunctional, Long-Lived CD8+ Memory T CellsSang Froid in a time of trouble: is a vaccine against HIV possible?Improved Efficacy of a Gene Optimised Adenovirus-based Vaccine for Venezuelan Equine Encephalitis VirusVaccines: the Fourth CenturyDifferent Vaccine Vectors Delivering the Same Antigen Elicit CD8+ T Cell Responses with Distinct Clonotype and Epitope SpecificityHeterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical TrialsAltering an artificial Gagpolnef polyprotein and mode of ENV co-administration affects the immunogenicity of a clade C HIV DNA vaccineImproved innate and adaptive immunostimulation by genetically modified HIV-1 protein expressing NYVAC vectorsImproved NYVAC-based vaccine vectorsIn vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteersPriming immunization with DNA augments immunogenicity of recombinant adenoviral vectors for both HIV-1 specific antibody and T-cell responsesStructural allele-specific patterns adopted by epitopes in the MHC-I cleft and reconstruction of MHC:peptide complexes to cross-reactivity assessmentDevelopments in HIV-1 immunotherapy and therapeutic vaccination.Prospects for control of emerging infectious diseases with plasmid DNA vaccines.Human immunodeficiency virus vaccine trialsPhase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B'/C candidate vaccine.Enhancement of the priming efficacy of DNA vaccines encoding dendritic cell-targeted antigens by synergistic toll-like receptor ligands.Phase 1 safety and immunogenicity evaluation of ADVAX, a multigenic, DNA-based clade C/B' HIV-1 candidate vaccineHigh-throughput high-resolution class I HLA genotyping in East Africa.Impaired cell surface expression of HLA-B antigens on mesenchymal stem cells and muscle cell progenitors.Boosting functional avidity of CD8+ T cells by vaccinia virus vaccination depends on intrinsic T-cell MyD88 expression but not the inflammatory milieu.Insertion of vaccinia virus C7L host range gene into NYVAC-B genome potentiates immune responses against HIV-1 antigensHIV-1 vaccine development after STEP.Novel directions in HIV-1 vaccines revealed from clinical trialsDNA prime-protein boost increased the titer, avidity and persistence of anti-Abeta antibodies in wild-type mice.Efficacy of multivalent adenovirus-based vaccine against simian immunodeficiency virus challengeNonreplicating vectors in HIV vaccines.Antigen engineering can play a critical role in the protective immunity elicited by Yersinia pestis DNA vaccines.Mosaic vaccines elicit CD8+ T lymphocyte responses that confer enhanced immune coverage of diverse HIV strains in monkeys.Dendritic cell targeted HIV gag protein vaccine provides help to a DNA vaccine including mobilization of protective CD8+ T cells.
P2860
Q21089693-AF64C15A-8BE0-42A1-A6B9-2575F5AD32C7Q21135240-CE2A3DBC-4F66-4FE7-8335-7B97BAFD3FCFQ24652185-1BC4BCA6-1EAD-474B-AC0C-1E6334255235Q24654458-BC384269-91F5-44E7-80BD-2437F65C4930Q26740042-31874AB8-8855-42F6-8C4A-E862DA4400ABQ26861148-09F3B95C-EE5D-40C4-9F95-1AD7039BC448Q26995078-7AB18A20-CF5C-40E9-8A7A-28AEFE7C8179Q26995905-047B159F-DEA5-48B0-A843-CACAF3C2ABB5Q27024614-52D74E28-1646-4AA6-ADF1-CF824E7FD0BFQ27320923-1F93E847-5F19-4E66-A6A3-D5EC1AE69976Q27487038-64863777-AB75-47D3-B658-D1071EFE2651Q27487961-46140A65-90F2-4A84-9B3F-330506102D4AQ27489413-E69EEA22-3211-4FD5-BE59-AB4BFA807CC1Q27490454-54BA371D-6829-4C26-BE8B-5C1EEB5E626AQ27646554-0A09CAC8-AF8F-408C-8B97-942C990A1D7FQ28394899-C7D27A5B-03F1-40AF-A037-EA2586390868Q28482252-E3719662-EC94-423B-BE73-34E2CA23875FQ28742751-E3B97BF1-9182-46D9-AE55-21A8F87A714DQ28742982-61221066-0425-4295-835A-5D2B0FA879B4Q28744555-25C2D019-0113-4AE9-AC60-4DA0CB714E9AQ28749120-4F5717D4-2053-455C-9853-CD34742E2C56Q28752409-E00A2E2B-4931-40DB-929F-24696C823F17Q30364312-4225412E-ED1F-454D-AC74-1F50CCECB862Q30380454-B6B41990-2C34-449B-B368-B2BC123A249AQ30424366-F88F994B-CCF6-4564-9679-8316819C77BAQ30977303-BDF5A5ED-F4F7-4B20-BD54-D2DE4CFC8EE9Q33489847-2CB24892-695A-49C7-87C0-A09ED848E6F6Q33527383-70BA5A40-C652-4CC1-B4F2-199E88474B4EQ33588595-C6D74294-608D-4ED9-8817-894FDF5FCB13Q33598281-8D82DE03-6F38-4C28-A3C1-CB3F91EE511FQ33602726-FC74815F-DEF7-4C2B-9AA5-14A9A0AD9B6FQ33627613-9DD1B602-106D-4330-9966-020A4643BF15Q33642318-64076449-8C9D-48F6-BF1C-60D504AB39A5Q33645528-9A5DEED9-44E7-4050-8BE4-6BCA0140B2B7Q33647708-78464FFD-1586-471A-A516-105B08A17C69Q33676444-1239FB91-0CA7-43EB-AB81-09888036A6EBQ33693891-F2BBC185-78ED-4F4A-B8CC-C65BE03C5A4EQ33698142-5245E0F0-1C5B-4704-B52F-810B1B02F187Q33712291-2CF4F286-2F12-4662-947C-0ACE6E719685Q33732729-122951D9-5B14-442E-AFE0-518BA52FC1F9
P2860
An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
An HIV-1 clade C DNA prime, NY ...... long-lasting T cell responses.
@ast
An HIV-1 clade C DNA prime, NY ...... long-lasting T cell responses.
@en
type
label
An HIV-1 clade C DNA prime, NY ...... long-lasting T cell responses.
@ast
An HIV-1 clade C DNA prime, NY ...... long-lasting T cell responses.
@en
prefLabel
An HIV-1 clade C DNA prime, NY ...... long-lasting T cell responses.
@ast
An HIV-1 clade C DNA prime, NY ...... long-lasting T cell responses.
@en
P2093
P2860
P50
P356
P1476
An HIV-1 clade C DNA prime, NY ...... long-lasting T cell responses.
@en
P2093
Abdel Babiker
Christiane Moog
Cristina Cellerai
Emmanuelle Medjitna-Rais
Gonzalo Tapia
James Tartaglia
Jean-Pierre Kraehenbuhl
Jonathan Weber
Mariano Esteban
P2860
P356
10.1084/JEM.20071331
P407
P577
2008-01-14T00:00:00Z